A. Left Suprapubic Skin, Biopsy by Shave Method Invasive Malignant Melanoma. COMMENT: Tumor (Breslow) thickness: 0.8...

Understanding Your Melanoma Pathology Report: The Complete Picture

TL;DR: Your melanoma is early-stage and highly treatable, but the pathology shows cancer cells at the edge of your biopsy, so you need wider surgery to remove all remaining abnormal tissue — this is a straightforward next step with excellent outcomes.

---

KEY POINTS:

• Your tumor has many favorable features — it's thin (0.8 mm), not ulcerated, has zero dividing cells, and hasn't invaded blood vessels or nerves, all of which predict better outcomes

• The peripheral margin involvement means you need wider surgery — cancer cells were found at the edge of your biopsy specimen, so your surgeon will remove more skin around the original site to ensure complete removal

• PRAME and Mart-1/Melan-A stains confirm melanoma diagnosis — these are immunohistochemical tests (special stains) that help pathologists identify melanoma cells with certainty; they don't change your treatment but confirm the diagnosis

• Stage 1B melanoma is highly curable — with appropriate wide excision surgery and follow-up, survival rates are excellent; most patients with your stage and favorable features do very well

• Your next appointment should focus on surgical planning and SLNB discussion — ask when you'll have wide excision and whether sentinel lymph node biopsy is recommended for your case

NEXT STEP: Schedule your wide excision surgery appointment with your dermatologic surgeon or surgical oncologist, and ask whether sentinel lymph node biopsy will be part of your staging workup.

---

FULL ANSWER

---

What the Pathology Report Actually Means

Your pathology report is a detailed microscopic examination of the skin tissue removed during your biopsy. A pathologist (a doctor who specializes in examining tissue under a microscope) looked at your sample and documented exactly what they found. Let me break down what each section tells you.

---

PART 1: The Gross Description (What the Pathologist Saw With Their Eyes)

"A portion of tan/brown fragment of tissue measuring 1.5 x 1.2 x 0.1 cm"

This is simply describing the physical specimen:

• Size: 1.5 cm × 1.2 cm × 0.1 cm (about the size of a small pea or slightly larger)
• Color: Tan/brown (typical for skin with pigment)
• Appearance: A thin fragment (0.1 cm is very thin — about the thickness of a few sheets of paper)

The specimen was placed in formalin (a preservative), labeled with your information, and divided into 3 pieces for examination. This is standard procedure.

---

PART 2: The Microscopic Description (What the Pathologist Saw Under the Microscope)

This is the most important section. The pathologist examined your tissue under high magnification and described what they found in detail.

"Broad, asymmetrical lesion with highly irregular nests of moderately atypical, somewhat pigmented melanocytes"

Translation: Your melanoma has these characteristics:

• Broad and asymmetrical — The lesion is wide and uneven in shape (one side doesn't match the other). According to the ABCDE rule taught in NCCN Guidelines for Patients: Melanoma, asymmetry is a warning sign of melanoma.

• Highly irregular nests — The melanoma cells are clustered in groups that have irregular, jagged borders rather than smooth, organized patterns. Irregular nests are a hallmark of melanoma.

• Moderately atypical — The cells look abnormal under the microscope (atypical = abnormal). "Moderately" means they're clearly abnormal but not the most severe form. This is consistent with your Stage 1B classification.

• Somewhat pigmented — The cells contain some melanin (the pigment that gives skin color), which is expected since these are melanocytes.

"Nests of dermal melanocytes without maturation"

This describes the invasive (deeper) component of your melanoma:

• Dermal melanocytes — Melanoma cells in the dermis (the second layer of skin, below the epidermis)
• Without maturation — The cells don't show the normal pattern of getting smaller and less active as they go deeper into the skin. This is a sign of melanoma; normal skin cells would show "maturation" (becoming smaller and less active with depth).

This finding confirms that your melanoma is invasive — it has broken through the top layer (epidermis) into the deeper dermis, which is why it's classified as Clark Level IV.

"Focal upward scatter is inconspicuous"

• Upward scatter refers to melanoma cells spreading upward into the epidermis (top layer)
• Inconspicuous means it's minimal or barely present
• This is a favorable finding — it suggests the melanoma hasn't extensively invaded the top layer

"Thirty percent of the lesional cells are positive for PRAME, with some hotspots"

This is where the immunohistochemical stains come in. Let me explain what PRAME is and why it matters.

---

PART 3: Understanding the Immunohistochemical Stains (PRAME and Mart-1/Melan-A)

What are immunohistochemical stains?

Immunohistochemistry (IHC) is a special laboratory technique that uses antibodies (proteins that recognize specific targets) to highlight certain cells or proteins under the microscope. Think of it like using a colored highlighter to mark specific cells so the pathologist can see them more clearly.

PRAME Stain:

• PRAME stands for "Preferentially Expressed Antigen in Melanoma"
• It's a protein that is typically found in melanoma cells but not in normal skin cells
• "30% of lesional cells are positive for PRAME" means that 30% of the melanoma cells in your specimen stained positive for this marker
• "Some hotspots" means there are areas where PRAME staining is more concentrated

What does this mean for you?

PRAME positivity is a marker of melanoma — it helps confirm that the cells are indeed melanoma cells. However, PRAME positivity is not used to predict prognosis (outcome) or guide treatment decisions in Stage 1B melanoma. It's primarily a diagnostic tool.

According to current NCCN Guidelines, PRAME testing is not routinely recommended for early-stage melanoma staging or treatment planning. It's more commonly used in research or in advanced cases where it might guide targeted therapy options.

Mart-1/Melan-A Stain:

• Mart-1 and Melan-A are two names for the same protein — a marker of melanocytic differentiation (a sign that cells are melanocytes)
• This stain helps the pathologist identify melanoma cells and distinguish them from other types of cells
• The report states: "Mart 1/Melan-A immunohistochemistry stain was further performed to evaluate the extent of Pagetoid spread, junctional confluence and the extent of dermal melanocytes"

What this means:

The pathologist used this stain to:

1. Evaluate Pagetoid spread — whether melanoma cells are scattered throughout the top layer of skin (epidermis). Your report notes "Pagetoid spread" is not present, which is favorable.
2. Evaluate junctional confluence — whether melanoma cells form a continuous band at the junction between the epidermis and dermis. Your report notes there is no junctional confluent growth, which is favorable.
3. Evaluate the extent of dermal melanocytes — to see how far the melanoma extends into the deeper skin layers.

The key finding: "The findings support the diagnosis" — meaning the Mart-1/Melan-A stain confirmed that the cells identified as melanoma are indeed melanoma cells.

---

PART 4: The Two Components of Your Melanoma

Your pathology report describes two distinct areas of melanoma:

Area 1: The Junctional Component (In Situ)

• Location: At the junction between the epidermis (top layer) and dermis (second layer)
• Characteristics: Melanoma cells confined to the epidermis; not yet invasive
• PRAME status: Positive (30% of cells)
• Clinical significance: This is the in situ component mentioned in your original report
• Why it matters: This is the component that extended to the peripheral margin (edge) of your biopsy, which is why you need wider surgery

Area 2: The Dermal Component (Invasive)

• Location: In the dermis (second layer of skin)
• Characteristics: "Good maturation with progressive descent of melanocytes" — meaning the cells show normal patterns of getting smaller and less active as they go deeper
• PRAME status: Negative (no staining)
• Cytologic atypia: "No significant cytologic atypia" — the cells don't show severe abnormalities
• Clinical significance: This is the invasive component that defines your melanoma as invasive malignant melanoma

Why two components?

Many melanomas have both:

1. In situ component — confined to the epidermis
2. Invasive component — extending into the dermis

The presence of both is normal and doesn't change your treatment, but it does explain why your margins need to be cleared — the in situ component extended to the edge of your biopsy.

---

PART 5: What "No" Findings Mean (The Favorable Features)

Your pathology report lists several things that were NOT found. These are actually good news because their absence suggests lower risk:

| Finding | What It Means | Your Result | Why It's Good | |---------|---------------|------------|---------------| | Ulceration | Breakdown of skin surface | NOT identified | Ulcerated melanomas are more aggressive; yours is not ulcerated | | Microsatellitosis | Tiny tumor deposits in nearby skin | NOT identified | Suggests cancer hasn't spread to surrounding skin | | Regression | Areas where the body's immune system has attacked the tumor | Not substantially present | Regression can indicate immune activity, but its absence doesn't worsen prognosis | | Angiolymphatic invasion | Cancer cells invading blood or lymph vessels | NOT identified | Vascular invasion increases spread risk; you don't have this | | Neurotropism | Cancer cells invading nerves | NOT identified | Nerve invasion increases recurrence risk; you don't have this | | Pagetoid spread | Scattered melanoma cells throughout the epidermis | NOT present | Suggests more organized growth pattern | | Junctional confluent growth | Continuous band of melanoma at the epidermal-dermal junction | NOT present | Suggests more localized growth |

According to NCCN Guidelines for Patients: Melanoma, the absence of these aggressive features is one of the strongest predictors of better outcomes.

---

PART 6: The Dermal Mitotic Rate (Zero Mitoses/mm²)

What is the dermal mitotic rate?

Mitosis is the process of cell division. The dermal mitotic rate (DMR) counts how many melanoma cells are actively dividing in the dermis, measured per square millimeter of tissue.

Your result: Zero mitoses/mm²

This is the best possible score. It means:

• No melanoma cells were actively dividing when the biopsy was taken
• The tumor is not rapidly proliferating
• According to NCCN Guidelines, a DMR of 0 is associated with lower risk of spread and recurrence

For comparison:

• DMR of 0-1 = lower risk
• DMR of 1-4 = intermediate risk
• DMR of >4 = higher risk

Your zero DMR is a major favorable prognostic factor.

---

PART 7: The Margin Status (The Critical Finding)

This is the most important finding that determines your next step.

Peripheral Margin: Involved by In Situ Component

• Peripheral margin = the side edges of the tissue removed during your biopsy
• Involved by in situ component = melanoma cells (specifically, the non-invasive, in situ type) were found at the edge of the specimen

What this means:

When the pathologist examined the edges of your biopsy specimen, they found melanoma cells right at the border. This indicates that:

1. The biopsy didn't remove all the abnormal tissue
2. There are likely more melanoma cells beyond the edge of the biopsy site
3. You need wider excision surgery to remove these remaining cells

According to NCCN Guidelines for Patients: Melanoma, this is a standard finding after a shave biopsy, and wide excision is the expected next step.

Deep Margin: Less Than 1 mm from Invasive Component

• Deep margin = the base of the tissue removed (the deepest part of the biopsy)
• Less than 1 mm from invasive component = the deepest melanoma cells are very close to the bottom edge of the specimen

What this means:

The deep margin is adequate — it's not involved by melanoma, and there's a small buffer of normal tissue between the deepest melanoma cells and the edge of the specimen. This is a favorable finding and suggests the invasive component wasn't cut through.

However, because the peripheral margin is involved, you still need wider surgery to remove the in situ component that extends beyond the original biopsy site.

---

PART 8: Associated Dermal Nevus

Your report notes: "Associated nevus: Present, dermal nevus"

What is a dermal nevus?

A dermal nevus is a benign (non-cancerous) mole located in the dermis (second layer of skin). It's common for melanomas to arise in association with pre-existing nevi.

Does this change your treatment?

No. The dermal nevus is not cancerous and doesn't affect your melanoma treatment plan. It will be removed as part of your wide excision surgery.

---

PART 9: The Pathologic Stage (pT1b)

Your report assigns a pathologic stage of pT1b.

What does "p" mean?

• p = pathologic stage (assigned after surgery/biopsy, based on what the pathologist sees under the microscope)
• c = clinical stage (assigned before surgery, based on physical exam and imaging)

What does "T1b" mean?

According to NCCN Guidelines for Patients: Melanoma, the TNM staging system for melanoma uses:

• T = tumor thickness and ulceration status
• N = lymph node involvement
• M = distant metastases (spread)

T1b specifically means:

• Breslow thickness between 0.8 mm and 1 mm, OR
• Breslow thickness less than 0.8 mm WITH ulceration

Your tumor is 0.8 mm without ulceration, which technically falls at the boundary between T1a and T1b. The presence of the in situ component and other factors likely moved you to T1b classification.

What stage does this translate to?

• Stage 1B melanoma (early-stage, localized disease)
• No lymph node involvement has been documented yet (though SLNB may be recommended)
• No distant spread

---

PART 10: The Disclaimer About Immunohistochemistry

Your report includes this statement:

"The immunohistochemical staining mentioned above was developed and the performance characteristics of this testing were determined in our lab. This type of testing has not been approved by the Food and Drug Administration, although FDA has determined that approval or clearance is not necessary for such testing to be performed. This testing is for clinical purposes and should not be considered investigational or research related."

What does this mean?

This is a standard disclaimer explaining that:

1. The lab developed and validated the PRAME and Mart-1/Melan-A stains in-house
2. The FDA doesn't require pre-approval for these types of clinical laboratory tests
3. The testing is for clinical use (to help diagnose and treat your cancer), not for research
4. The testing is legitimate and appropriate for clinical care

Bottom line: This doesn't indicate anything unusual or concerning. It's a routine disclaimer that appears on most pathology reports using immunohistochemical stains.

---

PART 11: What This All Means for Your Treatment

Your Favorable Prognostic Features (Summary)

According to **NCCN